The content on this site is intended for healthcare professionals only
ecancer round up of the multiple myeloma news to come out of the American Society of Hematology meeting in New Orleans 5-8th December 2009.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
Teclistamab in combination with subcutaneous daratumumab and lenalidomide shows promising results in patients with multiple myeloma
